Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

Research output: Contribution to journalJournal articleResearchpeer-review

  1. GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism

    Research output: Contribution to journalReviewResearchpeer-review

  2. Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuromedin U Does Not Act as a Decretin in Rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mechanisms Preserving Insulin Action during High Dietary Fat Intake

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Pathogenic mutations in the appetite-regulating melanocortin-4 receptor (MC4R) represent the most common cause of monogenic obesity with limited treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause weight loss by reducing appetite. We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8). Liraglutide decreased body weight by 6.8 kg ± 1.8 kg in individuals with pathogenic MC4R mutations and by 6.1 kg ± 1.2 kg in control participants. Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups. Thus, liraglutide induced an equal, clinically significant weight loss of 6% in both groups, indicating that the appetite-reducing effect of liraglutide is preserved in MC4R causal obesity and that liraglutide acts independently of the MC4R pathway. Thus, liraglutide could be an effective treatment of the most common form of monogenic obesity.

Original languageEnglish
JournalCell Metabolism
Volume28
Issue number1
Pages (from-to)23-32
ISSN1550-4131
DOIs
Publication statusPublished - 1 Aug 2018

ID: 54585372